Literature DB >> 24056040

The E104D mutation increases the susceptibility of human triosephosphate isomerase to proteolysis. Asymmetric cleavage of the two monomers of the homodimeric enzyme.

Ignacio De La Mora-De La Mora1, Alfredo Torres-Larios, Guillermo Mendoza-Hernández, Sergio Enriquez-Flores, Adriana Castillo-Villanueva, Sara T Mendez, Itzhel Garcia-Torres, Angélica Torres-Arroyo, Saúl Gómez-Manzo, Jaime Marcial-Quino, Jesús Oria-Hernández, Gabriel López-Velázquez, Horacio Reyes-Vivas.   

Abstract

The deficiency of human triosephosphate isomerase (HsTIM) generates neurological alterations, cardiomyopathy and premature death. The mutation E104D is the most frequent cause of the disease. Although the wild type and mutant exhibit similar kinetic parameters, it has been shown that the E104D substitution induces perturbation of an interfacial water network that, in turn, reduces the association constant between subunits promoting enzyme inactivation. To gain further insight into the effects of the mutation on the structure, stability and function of the enzyme, we measured the sensitivity of recombinant E104D mutant and wild type HsTIM to limited proteolysis. The mutation increases the susceptibility to proteolysis as consequence of the loss of rigidity of its overall 3-D structure. Unexpectedly, it was observed that proteolysis of wild type HsTIM generated two different stable nicked dimers. One was formed in relatively short times of incubation with proteinase K; as shown by spectrometric and crystallographic data, it corresponded to a dimer containing a nicked monomer and an intact monomer. The formation of the other nicked species requires relatively long incubation times with proteinase K and corresponds to a dimer with two clipped subunits. The first species retains 50% of the original activity, whereas the second species is inactive. Collectively, we found that the E104D mutant is highly susceptible to proteolysis, which in all likelihood contributes to the pathogenesis of enzymopathy. In addition, the proteolysis data on wild type HsTIM illustrate an asymmetric conduct of the two monomers.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  3-chloroacetol phosphate; 5,5′-dithio-bis (2-nitrobenzoic acid); 8-anilinonaphthalene 1-sulphonate; ANS; CAP; Conformational change; DTNB; HsTIM; Limited proteolysis; PVDF; TIM deficiency; Triosephosphate isomerase; X-ray crystallography; human triosephosphate isomerase; polyvinylidene difluoride

Mesh:

Substances:

Year:  2013        PMID: 24056040     DOI: 10.1016/j.bbapap.2013.08.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Allosteric Interactions by p53 mRNA Govern HDM2 E3 Ubiquitin Ligase Specificity under Different Conditions.

Authors:  Ixaura Medina-Medina; Paola García-Beltrán; Ignacio de la Mora-de la Mora; Jesús Oria-Hernández; Guy Millot; Robin Fahraeus; Horacio Reyes-Vivas; José G Sampedro; Vanesa Olivares-Illana
Journal:  Mol Cell Biol       Date:  2016-07-29       Impact factor: 4.272

2.  Structural effects of protein aging: terminal marking by deamidation in human triosephosphate isomerase.

Authors:  Ignacio de la Mora-de la Mora; Alfredo Torres-Larios; Sergio Enríquez-Flores; Sara-Teresa Méndez; Adriana Castillo-Villanueva; Saúl Gómez-Manzo; Gabriel López-Velázquez; Jaime Marcial-Quino; Angélica Torres-Arroyo; Itzhel García-Torres; Horacio Reyes-Vivas; Jesús Oria-Hernández
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

3.  The stability of G6PD is affected by mutations with different clinical phenotypes.

Authors:  Saúl Gómez-Manzo; Jessica Terrón-Hernández; Ignacio De la Mora-De la Mora; Abigail González-Valdez; Jaime Marcial-Quino; Itzhel García-Torres; America Vanoye-Carlo; Gabriel López-Velázquez; Gloria Hernández-Alcántara; Jesús Oria-Hernández; Horacio Reyes-Vivas; Sergio Enríquez-Flores
Journal:  Int J Mol Sci       Date:  2014-11-17       Impact factor: 5.923

4.  Novel giardicidal compounds bearing proton pump inhibitor scaffold proceeding through triosephosphate isomerase inactivation.

Authors:  B Hernández-Ochoa; G Navarrete-Vázquez; C Nava-Zuazo; A Castillo-Villanueva; S T Méndez; A Torres-Arroyo; S Gómez-Manzo; J Marcial-Quino; M Ponce-Macotela; Y Rufino-González; M Martínez-Gordillo; G Palencia-Hernández; N Esturau-Escofet; E Calderon-Jaimes; J Oria-Hernández; H Reyes-Vivas
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

5.  Identification of protein quality control regulators using a Drosophila model of TPI deficiency.

Authors:  Stacy L Hrizo; Samantha L Eicher; Tracey D Myers; Ian McGrath; Andrew P K Wodrich; Hemanth Venkatesh; Daniel Manjooran; Sabrina Swoger; Kim Gagnon; Matthew Bruskin; Maria V Lebedev; Sherry Zheng; Ana Vitantonio; Sungyoun Kim; Zachary J Lamb; Andreas Vogt; Maura R Z Ruzhnikov; Michael J Palladino
Journal:  Neurobiol Dis       Date:  2021-02-15       Impact factor: 5.996

6.  Itavastatin and resveratrol increase triosephosphate isomerase protein in a newly identified variant of TPI deficiency.

Authors:  Andrew P VanDemark; Stacy L Hrizo; Samantha L Eicher; Jules Kowalski; Tracey D Myers; Megan R Pfeifer; Kacie N Riley; Dwight D Koeberl; Michael J Palladino
Journal:  Dis Model Mech       Date:  2022-05-17       Impact factor: 5.732

7.  Deamidated Human Triosephosphate Isomerase is a Promising Druggable Target.

Authors:  Sergio Enríquez-Flores; Luis Antonio Flores-López; Itzhel García-Torres; Ignacio de la Mora-de la Mora; Nallely Cabrera; Pedro Gutiérrez-Castrellón; Yoalli Martínez-Pérez; Gabriel López-Velázquez
Journal:  Biomolecules       Date:  2020-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.